Earlier studies of associations of levels of circulating biomarkers of extracellular matrix turnover with mortality risk have so far mainly been made in groups of patients with manifest cardiovascular disease or cancer.
The study, by Katherine M. Flegal and her associates at the C.D.C. and the National Institutes of Health, found that all adults categorized as overweight and most of those categorized as obese have a lower mortality risk than so-called normal-weight individuals.
Thus, its utility is not diminished by the fact that the relationship of serum cystatin C with mortality risk in diabetes, so well documented in nondiabetic subjects (12, 13, 19), is only marginally confirmed in our diabetic cohorts.
And the results suggest they were right: Among the 37,698 men and 83,644 women who were tracked, as meat consumption increased, so did mortality risk.
So, for mortality risk, the analyses could have been based on four categories of BMI/metabolic health phenotypes.
It has been shown that reduction of body weight as small as 5% substantially reduces the morbidity and mortality risks of obesity, so even if recognizing and treating ADHD is only a modest contributor to reducing body fat mass, it is worthwhile on that grounds alone.
PE's mortality risk was low or intermediate low so there was no need for thrombolysis in all cases.
The estimates also assume that there is no adaptation to extreme heat, so that the mortality risk from heat waves is constant over time.
The increased mortality risk was greater, but not significantly so, for spells of absence with a non-psychotic psychiatric diagnosis (hazard ratio 1.9), and this increased risk was seen with both subcategories "neurosis" (1.9) and "neurosis ill-defined" (2.0).
This analysis allows us to test whether mortality risk is truly additive over time, and if so, to compare the sum of risks and to make inference on the difference between sums of risks.
